For men with advanced prostate cancer, receipt of abiraterone or enzalutamide is linked with an increased risk for major metabolic or cardiovascular adverse events, according to a study published in the Journal of the National Cancer Institute. Lillian Y. Lai, MD, and colleagues examined the association between the use of abiraterone or enzalutamide and the risk for metabolic or cardiovascular adverse events while on treatment among men with advanced prostate cancer. The occurrence of a major metabolic or cardiovascular adverse event was assessed as the primary composite outcome; the occurrence of a minor metabolic or cardiovascular adverse event was also examined. Men receiving abiraterone had an increased risk for both a major composite event and a minor composite event compared with those not receiving abiraterone (HRs, 1.77 [95% CI, 1.53- 2.05] and 1.24 [95% CI, 1.05-1.47], respectively). Men receiving enzalutamide had an increased risk for a major composite adverse event (HR, 1.22; 95% CI, 1.01-1.48), but not a minor composite adverse event (HR, 1.04; 95% CI, 0.83-1.30).
